Switching from GLP-1 Injections to Wegovy Pill Shows Additional Weight Loss of 4.1%
Healthline reports on the OCTANE study, a retrospective real-world analysis presented at the 2026 EASD meeting and not yet peer reviewed. Among 194 adults with overweight or obesity who switched from injectable semaglutide or tirzepatide to oral semaglutide, average weight loss was 4.1% over 3 months. The observational design cannot show the switch caused the loss, and weights were self-reported.
Why it matters: Relevant to Maryland adults on injectable GLP-1 weight loss medication who are curious about pill options, and to clinicians managing medical weight loss.
A summary of another publisher's reporting, written with AI and checked automatically against the story. The reporting belongs to healthline.com. October 6, 2026.